Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

PURPOSE: Based on the preclinical evidence of topoisomerase I (Topo-1) upregulation by mitomycin C(MMC) and decreased NF-κB activation by celecoxib, we evaluated combinations of irinotecan/MMC and irinotecan/MMC/celecoxib in patients with advanced solid malignancies. PATIENTS–METHODS: Initially, pat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Xu, Y., Kolesar, J. M., Schaaf, L. J., Drengler, R., Duan, W., Otterson, G., Shapiro, C., Kuhn, J., Villalona-Calero, M. A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2008
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3933356/
https://ncbi.nlm.nih.gov/pubmed/18795290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0826-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items